- Home
- FTDR vs VRNA Comparison
FTDR vs VRNA Comparison
Compare FTDR & VRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FTDR
- VRNA
- Stock Information
- Founded
- FTDR 1971
- VRNA 2005
- Country
- FTDR United States
- VRNA United Kingdom
- Employees
- FTDR N/A
- VRNA N/A
- Industry
- FTDR Diversified Commercial Services
- VRNA Biotechnology: Pharmaceutical Preparations
- Sector
- FTDR Finance
- VRNA Health Care
- Exchange
- FTDR Nasdaq
- VRNA Nasdaq
- Market Cap
- FTDR 3.6B
- VRNA 3.4B
- IPO Year
- FTDR 2018
- VRNA 2017
- Fundamental
- Price
- FTDR $57.10
- VRNA $67.96
- Analyst Decision
- FTDR Hold
- VRNA Strong Buy
- Analyst Count
- FTDR 6
- VRNA 7
- Target Price
- FTDR $48.60
- VRNA $57.14
- AVG Volume (30 Days)
- FTDR 581.7K
- VRNA 1.3M
- Earning Date
- FTDR 02-27-2025
- VRNA 02-27-2025
- Dividend Yield
- FTDR N/A
- VRNA N/A
- EPS Growth
- FTDR 42.94
- VRNA N/A
- EPS
- FTDR 3.00
- VRNA N/A
- Revenue
- FTDR $1,827,000,000.00
- VRNA $5,624,000.00
- Revenue This Year
- FTDR $4.78
- VRNA N/A
- Revenue Next Year
- FTDR $6.38
- VRNA $571.44
- P/E Ratio
- FTDR $19.44
- VRNA N/A
- Revenue Growth
- FTDR 4.16
- VRNA 1127.95
- 52 Week Low
- FTDR $29.41
- VRNA $11.39
- 52 Week High
- FTDR $63.49
- VRNA $68.64
- Technical
- Relative Strength Index (RSI)
- FTDR 43.77
- VRNA 76.88
- Support Level
- FTDR $56.43
- VRNA $62.24
- Resistance Level
- FTDR $60.19
- VRNA $65.50
- Average True Range (ATR)
- FTDR 1.54
- VRNA 2.78
- MACD
- FTDR -0.30
- VRNA 0.22
- Stochastic Oscillator
- FTDR 12.86
- VRNA 94.86
About FTDR Frontdoor Inc.
Frontdoor Inc is a United States-based company that provides home service plans. It owns multiple home service brands including American Home Shield, HSA, OneGuard, and Landmark brands. Through its home service plans, the company helps its customers maintain their homes and protect against costly and unexpected breakdowns of essential home systems and appliances.
About VRNA Verona Pharma plc
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.